| Schedule of Financial Information Including Significant Segment Expenses by Program |
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the three and six months ended September 30, 2026 and 2025: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
September 30, | | Six Months Ended
September 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Operating expenses: | (Amounts in thousands) | | Direct research and development expenses by program: | | | | | | | | | RP1 program costs by study: | | | | | | | | | IGNYTE | $ | 903 | | | $ | 2,562 | | | 1,578 | | | 6,014 | | | ARTACUS | 648 | | | 1,616 | | | 1,132 | | | 3,235 | | | CERPASS | 176 | | | 1,433 | | | (94) | | | 2,640 | | | IGNYTE-3 | 6,818 | | | 6,474 | | | 14,768 | | | 11,335 | | | Other RP1 study costs | 39 | | | 5,539 | | | 1,439 | | | 9,963 | | | RP2 | 9,439 | | | 5,253 | | | 18,266 | | | 9,128 | | | RP3 | 303 | | | 580 | | | 549 | | | 1,437 | | | Unallocated research and development expenses¹: | 16,039 | | | 34,420 | | | 46,006 | | | 71,969 | | | Selling, general and administrative | 21,916 | | | 26,414 | | | 40,885 | | | 58,994 | | | Total operating expenses | 56,281 | | | 84,291 | | | 124,529 | | | 174,715 | | | Loss from operations | (56,281) | | | (84,291) | | | (124,529) | | | (174,715) | | | Other (expense) income, net | (840) | | | $ | 1,191 | | | $ | (2,358) | | | $ | 4,922 | | | | | | | | | | | | | | | | | | | Net loss | (57,121) | | | (83,100) | | | (126,887) | | | (169,793) | |
¹Includes personnel-related costs and other costs |